---
title: "Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 8-K: FY2025 Q4 Revenue: USD 977.2 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275752142.md"
published_at: "2026-02-12T12:04:25.000Z"
---

# Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 8-K: FY2025 Q4 Revenue: USD 977.2 M

Revenue: As of FY2025 Q4, the actual value is USD 977.2 M.

EPS: As of FY2025 Q4, the actual value is USD 0.1.

EBIT: As of FY2025 Q4, the actual value is USD 84.4 M.

### Fourth Quarter 2025 (Q4-25) Financial Results

#### Segment Revenue

-   **Bruker Scientific Instruments (BSI)**: $907.7 million, a decrease of 0.4% year-over-year (YoY), with an organic decrease of 5.1%.
-   **Bruker Energy & Supercon Technologies (BEST)**: $71.5 million, a decrease of 0.8% YoY, with an organic decrease of 5.1%.

#### Operational Metrics

-   **GAAP Operating Income**: $76.3 million, compared to $72.1 million in Q4-24.
-   **Non-GAAP Operating Income**: $153.5 million, compared to $177.5 million in Q4-24.
-   **Non-GAAP Operating Margin**: 15.7%, compared to 18.1% in Q4-24.

#### Cash Flow

-   **Cash Flows from Operating Activities**: $229.8 million.
-   **Non-GAAP Free Cash Flow**: $207.2 million.

### Fiscal Year 2025 (FY25) Financial Results

#### Segment Revenue

-   **Bruker Scientific Instruments (BSI)**: $3.17 billion, an increase of 2.4% compared to FY24, with organic revenue decreasing by 3.5%.
-   **Bruker Energy & Supercon Technologies (BEST)**: $270.9 million, a decrease of 4.3% compared to FY24, with an organic decrease of 5.4%.

#### Operational Metrics

-   **GAAP Operating Income**: $68.2 million, compared to $253.1 million in FY24, which includes non-cash impairment charges to goodwill and intangible assets totaling $127.2 million and restructuring charges of $77.4 million.
-   **Non-GAAP Operating Income**: $433.1 million, a decrease of 16.4% compared to $518.0 million in FY24.
-   **Non-GAAP Operating Margin**: 12.6%, compared to 15.4% in FY24.
-   **Cost of Revenue**: $1,858.8 million.
-   **Selling, General and Administrative Expenses**: $946.5 million.
-   **Research and Development Expenses**: $395.2 million.
-   **Goodwill Impairment Charge**: $96.5 million.
-   **Other Charges, net**: $71.3 million.
-   **Interest and Other Expense, net**: - $46.2 million.
-   **Income Tax Provision**: $29.3 million.
-   **Equity in Losses of Unconsolidated Investees, net of tax**: - $1.0 million.
-   **Net Income (Loss) Attributable to Bruker Corporation**: - $8.6 million.
-   **Dividends on Series A Mandatory Convertible Preferred Stock**: $13.9 million.

#### Cash Flow

-   **Cash Flows from Operating Activities**: $134.1 million.
-   **Non-GAAP Free Cash Flow**: $43.3 million.

### Fiscal Year 2026 (FY26) Financial Outlook

-   Bruker Corporation anticipates FY26 revenues to range between $3.57 and $3.60 billion, reflecting a 4% to 5% year-over-year growth, with organic growth projected at 1% to 2%. The company expects a return to organic revenue growth by the second quarter of 2026, despite an expected organic decline in Q1-26.

### Related Stocks

- [BRKRP.US - Bruker Corp Pref Shares BRKRP 6.375 09/01/2028](https://longbridge.com/en/quote/BRKRP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Twilio｜8-K：2025 财年 Q4 营收 13.66 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275808864.md) |
| Parsons｜8-K：2025 财年 Q4 营收 16.04 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275596521.md) |
| Atomera｜8-K：2025 财年 Q4 营收 5 万美元 |  | [Link](https://longbridge.com/en/news/275813130.md) |
| 怡安集团｜10-K：2025 财年营收 172 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275945420.md) |
| Ryan Specialty｜8-K：2025 财年 Q4 营收 7.51 亿美元 |  | [Link](https://longbridge.com/en/news/275808003.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
